Nyxoah S.A. (EBR: NYXH)

Market Cap	291.63M
Revenue (ttm)	5.08M
Net Income (ttm)	-52.98M
Shares Out	37.39M
EPS (ttm)	-1.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,380
Open	7.84
Previous Close	7.84
Day's Range	7.60 - 7.88
52-Week Range	3.79 - 17.60
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 13, 2025

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 147
• Stock Exchange: Euronext Brussels
• Ticker Symbol: NYXH

Financial Performance

In 2023, Nyxoah's revenue was 4.35 million, an increase of 40.99% compared to the previous year's 3.08 million. Losses were -43.21 million, 38.4% more than in 2022.